Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
The farnesoid X receptor (FXR) regulates bile acid, lipid and glucose metabolism. Here we show that treatment of mice with glycine-β-muricholic acid (Gly-MCA) inhibits FXR signalling exclusively in intestine, and improves metabolic parameters in mouse models of obesity. Gly-MCA is a selective high-affinity FXR inhibitor that can be administered orally and prevents, or reverses, high-fat diet-induced and genetic obesity, insulin resistance and hepatic steatosis in mice. The high-affinity FXR agonist GW4064 blocks Gly-MCA action in the gut, and intestine-specific Fxr -null mice are unresponsive to the beneficial effects of Gly-MCA. Mechanistically, the metabolic improvements with Gly-MCA depend on reduced biosynthesis of intestinal-derived ceramides, which directly compromise beige fat thermogenic function. Consequently, ceramide treatment reverses the action of Gly-MCA in high-fat diet-induced obese mice. We further show that FXR signalling in ileum biopsies of humans positively correlates with body mass index. These data suggest that Gly-MCA may be a candidate for the treatment of metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, some data also indicate that antagonism of intestinal FXR signaling could improve metabolic parameters in murine models of NAFLD [256,257].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [256]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beige Adipocytes Are a Distinct Type of Thermogenic Fat Cell in Mouse and Human
Wu, J., Boström, P., Sparks, L. M., Ye, L., Choi, J. H., Giang, A.-H., Khandekar, M., Virtanen, K. A., Nuutila, P., Schaart, G., et al. (2012) · Cell · doi:10.1016/j.cell.2012.05.016 · Cited by 3,319
The RXR heterodimers and orphan receptors
Mangelsdorf, D. J., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90200-7 · Cited by 3,158 · cited 1×
“All individuals fulfilled the following inclusion criteria: (1) no significant alcohol consumption (the definition of significant alcohol consumption has been inconsistent and ranged from 41 alcoholic beverage (10 g of alcohol per one drink unit) per day to 440 g per day); (2) no significant acute or chronic inflammat…”
BackgroundKanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Brown and beige fat: Development, function and therapeutic potential
Harms, M., & Seale, P. (2013) · Nature Medicine · doi:10.1038/nm.3361 · Cited by 2,328
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Self-citationBile acids: regulation of synthesis
Chiang, J. Y. L. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900010-jlr200 · Cited by 1,515
Petrovic, N., Walden, T. B., Shabalina, I. G., Timmons, J. A., Cannon, B., & Nedergaard, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.053942 · Cited by 1,263
Pleiotropic Roles of Bile Acids in Metabolism
de Aguiar Vallim, T. Q., Tarling, E. J., & Edwards, P. A. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.013 · Cited by 1,209
Cited by
Items 101–200 of 566
Gut commensal Christensenella minuta modulates host metabolism via acylated secondary bile acids
Liu, C., Du, M., Xie, L., Wang, W.-Z., Chen, B., Yun, C., Sun, X., Luo, X., Jiang, Y., Wang, K., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-023-01570-0 · Cited by 136
“No statistical methods were used to pre-determine sample sizes, but our sample sizes are similar to those reported in previous publications 26,47 .”
InfluentialSelf-citationThe role of the gut microbiota in health and cardiovascular diseases
Wang, L., Wang, S., Zhang, Q., He, C., Fu, C., & Wei, Q. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00091-2 · Cited by 122
Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
Jiao, T., Ma, Y., Guo, X., Ye, Y., & Xie, C. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00880-z · Cited by 136
“Other strategies targeting intestinal FXR including genetic knockout of FXR, gut bacteria modulation or treatment with a synthetic intestinal FXR-restricted antagonist glycine-β-MCA (GlyMCA) were shown to reduce intestine-derived and circulating ceramides by downregulation of intestinal ceramide synthesis-related gene…”
BackgroundSelf-citationMasse, K. E., & Lu, V. B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1169624 · Cited by 120
Fatty liver diseases, bile acids, and FXR
Zhu, Y., Liu, H., Zhang, M., & Guo, G. L. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.07.008 · Cited by 118
Ding, L., Yang, Q., Zhang, E., Wang, Y., Sun, S., Yang, Y., Tong, T., Ju, Z., Jiang, L., Wang, X., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.038 · Cited by 123
Alemán, J. O., Bokulich, N. A., Swann, J. R., Walker, J. M., De Rosa, J. C., Battaglia, T., Costabile, A., Pechlivanis, A., Liang, Y., Breslow, J. L., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1619-z · Cited by 117
“FXR inhibition improves obesity related metabolic dysfunction including insulin resistance [61].”
The power of small changes: Comprehensive analyses of microbial dysbiosis in breast cancer
Parida, S., & Sharma, D. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.001 · Cited by 116
“A dysbiotic microbiota is known to promote diet induced obesity via the farnesoid X receptor(FXR) pathway [90,91].”
BackgroundGut microbiota-derived metabolites as key actors in type 2 diabetes mellitus
Du, L., Li, Q., Yi, H., Kuang, T., Tang, Y. P., & Fan, G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112839 · Cited by 131
Farnesoid X receptor: A “homeostat” for hepatic nutrient metabolism
Massafra, V., & van Mil, S. W. C. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.10.003 · Cited by 122
Prattichizzo, F., Giuliani, A., Mensa’, E., Sabbatinelli, J., Nigris, V. D., Rippo, M. R., Sala, L. L., Procopio, A. D., Olivieri, F., & Ceriello, A. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.10.003 · Cited by 120
Mechanisms controlling hormone secretion in human gut and its relevance to metabolism
Martin, A. M., Sun, E. W., & Keating, D. J. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0399 · Cited by 109
Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation
Tian, Y., Cai, J., Gui, W., Nichols, R. G., Koo, I., Zhang, J., Anitha, M., & Patterson, A. D. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083691 · Cited by 106
Self-citationRole of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease
Xi, Y., & Li, H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109609 · Cited by 117
Bauer, P. V., Duca, F. A., Waise, T. M. Z., Dranse, H. J., Rasmussen, B. A., Puri, A., Rasti, M., O'Brien, C. A., & Lam, T. K. T. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.01.013 · Cited by 115
Moreno‐Navarrete, J. M., & Fernández‐Real, J. M. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09523-x · Cited by 115
Münzker, J., Haase, N., Till, A., Sucher, R., Haange, S., Nemetschke, L., Gnad, T., Jäger, E., Chen, J., Riede, S. J., et al. (2022) · Microbiome · doi:10.1186/s40168-022-01264-5 · Cited by 115
“Of note, previous studies on mice with intestine-specific Fxr deletion or pharmacological inhibition reported protection against obesity and hepatic steatosis when fed a HFD [43, 55].”
BackgroundMethodTargeting FXR and FGF19 to Treat Metabolic Diseases—Lessons Learned From Bariatric Surgery
Bozadjieva, N., Heppner, K. M., & Seeley, R. J. (2018) · Diabetes · doi:10.2337/dbi17-0007 · Cited by 104
“Interestingly, FXR expression levels in ileum biopsies from obese patients were positively correlated with BMI (25).”
BackgroundInfluentialLiao, Z., Sun, B., Zhang, Q., Jia, L., Wei, Y., Liang, M., & Xu, H. (2020) · Aquaculture · doi:10.1016/j.aquaculture.2020.734935 · Cited by 109
The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD
Hong, T., Chen, Y., Li, X., & Lü, Y. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6889533 · Cited by 123
Lei, Y., Tang, L., Chen, Q., Wu, L., He, W., Tu, D., Wang, S., Chen, Y., Liu, S., Xie, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34671-1 · Cited by 104
Bile acids activated receptors in inflammatory bowel disease
Biagioli, M., Marchianò, S., Carino, A., Di Giorgio, C., Santucci, L., Distrutti, E., & Fiorucci, S. (2021) · Cells · doi:10.3390/cells10061281 · Cited by 103
“Moreover, 6α/βMCA bile acid, the two main bile acids found in mice in addition to TCA, acts as an FXR antagonist [28,29].”
BackgroundEmerging targetome and signalome landscape of gut microbial metabolites
Zheng, X., Cai, X., & Hao, H. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.011 · Cited by 101
Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects
Legry, V., Francque, S., Haas, J. T., Verrijken, A., Caron, S., Chávez-Talavera, O., Vallez, E., Vonghia, L., Dirinck, E., Verhaegen, A., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01397 · Cited by 101
“showed that intestinal FXR activation promotes NAFLD and that its antagonism improves metabolic control and NAFLD in mouse models of obesity (49, 50).”
Disruption of Epithelial HDAC3 in Intestine Prevents Diet-Induced Obesity in Mice
Whitt, J., Woo, V., Lee, P., Moncivaiz, J., Haberman, Y., Denson, L., Tso, P., & Alenghat, T. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.017 · Cited by 98
Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)
Fiorucci, S., Biagioli, M., Sepe, V., Zampella, A., & Distrutti, E. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1763302 · Cited by 104
“Of relevance also iFXR antagonism by glycine-β-MCA, or bile acid sequestrants, reduces blood glucose and ameliorates insulin sensitivity [23,24], and have been proposed for the EXPERT OPINION ON INVESTIGATIONAL DRUGS 629”
BackgroundAn FGF15/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis
Wang, Y., Gunewardena, S., Li, F., Matye, D. J., Chen, C., Chao, X., Jung, T., Zhang, Y., Czerwiński, M., Ni, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17363-6 · Cited by 105
Capsaicin and Gut Microbiota in Health and Disease
Roşca, A. E., Ieșanu, M. I., Zahiu, C. D. M., Voiculescu, S. E., Paslaru, A. C., & Zăgrean, A. (2020) · Molecules · doi:10.3390/molecules25235681 · Cited by 115
Kim, T., Nason, S., Holleman, C., Pepin, M., Wilson, L., Berryhill, T. F., Wende, A. R., Steele, C., Young, M. E., Barnes, S., et al. (2018) · Diabetes · doi:10.2337/db17-1502 · Cited by 97
“Consistent with this observation, chronic treatment with a synthetic FXR agonist GW4063 accentuated DIO (40), whereas FXR inhibition via tauro-b-muricholic acid (41) or glycine-b-muricholic acid (42) correlates with improved metabolic function.”
Chiang, J. Y. L., Pathak, P., Liu, H., Donepudi, A., Ferrell, J., & Boehme, S. (2017) · Digestive Diseases · doi:10.1159/000450981 · Cited by 97
Sun, J., Fan, J., Li, T., Yan, X., & Jiang, Y. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c04817 · Cited by 106
Exogenous bile acids regulate energy metabolism and improve the health condition of farmed fish
Wang, L., Sagada, G., Wang, C., Liu, R., Li, Q., Zhang, C., & Yan, Y. (2022) · Aquaculture · doi:10.1016/j.aquaculture.2022.738852 · Cited by 106
Yun, C., Yan, S., Liao, B., Ding, Y., Qi, X., Zhao, M., Wang, K., Zhuo, Y., Nie, Q., Ye, C., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01041-8 · Cited by 110
“Notably, intestinal FXR signalling plays an important role in metabolic diseases, including obesity, insulin resistance and non-alcoholic fatty liver disease 35,36 .”
Self-citationIntestinal Farnesoid X Receptor Signaling Modulates Metabolic Disease
Gonzalez, F. J., Jiang, C., Xie, C., & Patterson, A. D. (2017) · Digestive Diseases · doi:10.1159/000450908 · Cited by 95
Self-citationNuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052668 · Cited by 95
“In obesity, modulation of FXR signaling proved to have beneficial effects [177].”
BackgroundBile Acid Receptors and the Gut–Liver Axis in Nonalcoholic Fatty Liver Disease
Xue, R., Su, L., Lai, S., Wang, Y., Zhao, D., Fan, J., Chen, W., Hylemon, P. B., & Zhou, H. (2021) · Cells · doi:10.3390/cells10112806 · Cited by 95
Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective
Feng, H., & Chen, Y. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i33.7463 · Cited by 94
The emerging role of the small intestinal microbiota in human health and disease
Ruigrok, R. A. A. A., Weersma, R. K., & Vich Vila, A. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2201155 · Cited by 91
“, FXR signaling inhibition reversed the metabolic dysfunctions associated with a high-fat diet and a genetic predisposition for metabolic related diseases, including obesity, insulin resistance, and fatty liver.(60) Moreover, FXR signaling was enriched in the distal ileal mucosa of obese individuals, and mRNA levels o…”
BackgroundKetogenic diet-induced bile acids protect against obesity through reduced calorie absorption
Li, X., Yang, J., Zhou, X., Dai, C., Kong, M., Xie, L., Liu, C., Liu, Y., Li, D., Ma, X., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01072-1 · Cited by 108
“Furthermore, inhibition of intestinal farnesoid X receptor (FXR) by specific BAs prevented obesity-related metabolic dysfunction in mice 24,25 .”
Self-citationEffects of Consuming Xylitol on Gut Microbiota and Lipid Metabolism in Mice
Uebanso, T., Kano, S., Yoshimoto, A., Naito, C., Shimohata, T., Mawatari, K., & Takahashi, A. (2017) · Nutrients · doi:10.3390/nu9070756 · Cited by 103
“Moreover, alteration of the bile acids composition regulates lipid and energy metabolism through the activation of the farnesoid X receptor (FXR) or G-protein-coupled receptors (GPCRs), such as TGR5 [13,14].”
BackgroundPathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease
Kuchay, M. S., Choudhary, N. S., & Ramos‐Molina, B. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00951.2024 · Cited by 115
Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer
Sinclair, P., Brennan, D. J., & le Roux, C. W. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0057-y · Cited by 91
FXR: structures, biology, and drug development for NASH and fibrosis diseases
Tian, S., Chen, S., Pan, C., & Li, Y. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00849-4 · Cited by 102
“Glycine-β-muricholic acid (Gly-βMCA), a derivative of T-β-MCA, is a selective high-affinity and stable FXR inhibitor that can be administered orally, decreasing fasting serum insulin levels and reversible weight loss in HFD obese mice [57].”
BackgroundLipid remodeling of adipose tissue in metabolic health and disease
Cho, Y. K., Lee, S., Lee, J. R., Doh, J., Park, J., Jung, Y., & Lee, Y. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01071-4 · Cited by 109
“Cer 2:0, which elevates endogenous sphingolipid levels through the salvage pathway, and D609, a sphingomyelin synthase inhibitor, attenuate mitochondrial respiration in iWAT primary adipocytes 69 and suppress the expression of thermogenic genes in beige adipocytes 147 .”
BackgroundBile acids affect intestinal barrier function through FXR and TGR5
Song, G., Xie, Y., Yi, L., Cheng, W., Jia, H., Shi, W., Liu, Q., Fang, L., Xue, S., Liu, D., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1607899 · Cited by 134
FXR modulators for enterohepatic and metabolic diseases
Wang, H., He, Q., Wang, G., Xu, X., & Hao, H. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1527906 · Cited by 87
“To the contrary, inhibition of intestinal FXR signal results in the reduced biosynthesis of intestinal-derived ceramides, which directly compromises beige fat thermogenic function and improves obesity [25].”
BackgroundUrsodeoxycholic acid accelerates bile acid enterohepatic circulation
Zhang, Y., Jiang, R., Zheng, X., Lei, S., Huang, F., Xie, G., Kwee, S. A., Yu, H., Farrar, C. E., Sun, B., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14705 · Cited by 95
“Conjugated MCAs are thought to be FXR antagonists (Jiang et al., 2015).”
BackgroundHui, S., Liu, Y., Chen, M., Wang, X., Lang, H., Zhou, M., Yi, L., & Mi, M. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900608 · Cited by 102
Self-citationZhao, J., Xie, C., Wang, K., Takahashi, S., Krausz, K. W., Lu, D., Wang, Q., Luo, Y., Gong, X., Mu, X., et al. (2020) · Toxicology Letters · doi:10.1016/j.toxlet.2020.08.007 · Cited by 88
“Ultra-performance liquid chromatography equipped with quadrupole time-of-flight mass spectroscopy (UPLC-ESI-QTOFMS, Waters, USA) was applied for metabolomic analysis as previously described (Jiang et al., 2015; Zhao et al., 2018).”
MethodSelf-citationMolecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases
Bruneau, A., Hundertmark, J., Guillot, A., & Tacke, F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.725390 · Cited by 88
“Moreover, authors showed an overexpression of FXR and its downstream effectors in the intestine of obese humans compared with lean controls, thus suggesting a role of FXR in the pathogenesis of metabolic syndromes in patients (71).”
BackgroundStanhope, K. L., Goran, M. I., Bosy‐Westphal, A., King, J. C., Schmidt, L. A., Schwarz, J. ‐., Stice, E., Sylvetsky, A. C., Turnbaugh, P. J., Bray, G. A., et al. (2018) · Obesity Reviews · doi:10.1111/obr.12699 · Cited by 87
“Previous studies in mice treated with an FXR inhibitor have shown that the decreases in liver fat were accompanied by unaffected energy intake and increased energy expenditure (321).”
BackgroundBile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease
Li, T., & Chiang, J. Y. L. (2020) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.09.03 · Cited by 91
“Decreased intestinal FXR activation as a result of genetic FXR knockout, modulation of gut microbiota or treatment with glycine-β-MCA has been shown to reduce ceramide synthesis and circulating ceramide and improve metabolic homeostasis in mice (166,167).”
BackgroundRecent advances on FXR-targeting therapeutics
Panzitt, K., Zollner, G., Marschall, H., & Wagner, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111678 · Cited by 94
“microbiome or via synthetically generated compounds [15, 19, 161, 167, 182, 185].”
BackgroundInfluentialSphingolipid metabolism in non-alcoholic fatty liver diseases
Régnier, M., Polizzi, A., Guillou, H., & Loiseau, N. (2018) · Biochimie · doi:10.1016/j.biochi.2018.07.021 · Cited by 94
Ducastel, S., Touche, V., Trabelsi, M.-S., Boulinguiez, A., Butruille, L., Nawrot, M., Peschard, S., Chávez-Talavera, O., Dorchies, E., Vallez, E., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-56743-x · Cited by 84
The Gut Microbiome: Connecting Diet, Glucose Homeostasis, and Disease
Howard, E. J., Lam, T. K. T., & Duca, F. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042220-012821 · Cited by 93
Bile acids-gut microbiota crosstalk contributes to the improvement of type 2 diabetes mellitus
Gao, R., Meng, X., Xue, Y., Mao, M., Liu, Y., Tian, X., Sui, B., Li, X., & Zhang, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1027212 · Cited by 92
Self-citationHost metabolism balances microbial regulation of bile acid signalling
Won, T. H., Arifuzzaman, M., Parkhurst, C. N., Miranda, I. C., Zhang, B., Hu, E., Kashyap, S., Letourneau, J., Jin, W., Fu, Y., et al. (2025) · Nature · doi:10.1038/s41586-024-08379-9 · Cited by 107
“Increased Cyp8b1 expression, which is largely independent of the intestinal FXR– FGF15 pathway 46–48 , suggests that liver FXR may also be affected by CDCA–MCY supplementation, or that other pathways contribute to FXR-dependent ileum-to-liver signalling 49 .”
InfluentialBile Acids, Their Receptors, and the Gut Microbiota
Poland, J. C., & Flynn, C. R. (2021) · Physiology · doi:10.1152/physiol.00028.2020 · Cited by 102
Nonsteroidal FXR Ligands: Current Status and Clinical Applications
Gege, C., Hambruch, E., Hambruch, N., Kinzel, O., & Kremoser, C. (2019) · Handbook of Experimental Pharmacology · doi:10.1007/164_2019_232 · Cited by 83
Developments in bile salt based therapies: A critical overview
Donkers, J. M., Abbing, R. L. P. R., & van de Graaf, S. F. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.12.018 · Cited by 80
Intestinal microbial metabolites in human metabolism and type 2 diabetes
Herrema, H., & Niess, J. H. (2020) · Diabetologia · doi:10.1007/s00125-020-05268-4 · Cited by 86
Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development
Li, T., & Chiang, J. Y. L. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000978 · Cited by 90
Role of Bile Acids in Bariatric Surgery
Wang, W., Cheng, Z., Wang, Y., Dai, Y., Zhang, X., & Hu, S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00374 · Cited by 88
Local and systemic effects of microbiome‐derived metabolites
Spivak, I., Fluhr, L., & Elinav, E. (2022) · EMBO Reports · doi:10.15252/embr.202255664 · Cited by 75
Xu, G., & Song, M. (2020) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2020.08.028 · Cited by 80
“Although global activation of FXR is beneficial in improving metabolic disorders [27, 30–32], the role of intestinal FXR signaling is mixed [28, 29, 33].”
BackgroundRecent Advances in the Medicinal Chemistry of Farnesoid X Receptor
Fang, Y., Hegazy, L., Finck, B. N., & Elgendy, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01017 · Cited by 75
Immunomodulatory functions of FXR
Fiorucci, S., Zampella, A., Ricci, P., Distrutti, E., & Biagioli, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111650 · Cited by 70
Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders
Fiorucci, S., Baldoni, M., Ricci, P., Zampella, A., Distrutti, E., & Biagioli, M. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.04.008 · Cited by 73
Nakada, E. M., Bhakta, N. R., Korwin-Mihavics, B. R., Kumar, A., Chamberlain, N., Bruno, S. R., Chapman, D. G., Hoffman, S. M., Daphtary, N., Aliyeva, M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.98101 · Cited by 73
Self-citationCarino, A., Biagioli, M., Marchianò, S., Fiorucci, C., Zampella, A., Monti, M. C., Scarpelli, P. T., Ricci, P., Distrutti, E., & Fiorucci, S. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.07.006 · Cited by 72
Yang, K., & Song, M. J. (2023) · Nutrients · doi:10.3390/nu15183970 · Cited by 88
“Activation of FXR and TGR5 by bile acids influences glucose and lipid metabolism, inflammation, and immune responses [66–68].”
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Wang, X. X., Xie, C., Libby, A. E., Ranjit, S., Levi, J., Myakala, K., Bhasin, K., Jones, B. A., Orlicky, D. J., Takahashi, S., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102530 · Cited by 75
“INT-767 activates FXR in both liver and intestine, in contrast with the findings that intestinal FXR inhibition is beneficial in preventing NASH (46).”
ResultSelf-citationMusso, G., Saba, F., Cassader, M., & Gambino, R. (2023) · Progress in Lipid Research · doi:10.1016/j.plipres.2023.101238 · Cited by 74
Metabolic signaling of ceramides through the FPR2 receptor inhibits adipocyte thermogenesis
Lin, H., Ma, C., Cai, K., Guo, L., Wang, X., Lv, L., Zhang, C., Lin, J., Zhang, D., Ye, C., et al. (2025) · Science · doi:10.1126/science.ado4188 · Cited by 81
Self-citationRecent Advances in Psoriasis Research; the Clue to Mysterious Relation to Gut Microbiome
Komine, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072582 · Cited by 68
“Their study provided evidence that FXR inhibition in the intestine by antioxidant “tempol” or by genetic ablation of FXR is effective in suppressing diet-induced obesity and insulin resistance [51,52].”
BackgroundEndogenous ethanol production in health and disease
Meijnikman, A. S., Nieuwdorp, M., & Schnabl, B. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00937-w · Cited by 83
“It is worth noting that many microbial species belonging to these families are used as beneficial probiotics 93,94 , and strains from different microbial families, or even bacteria of the same strain, can have both beneficial and harmful effects 95–97 .”
Browning, M. G., Pessoa, B. M., Khoraki, J., & Campos, G. M. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00334-4 · Cited by 69
Schumacher, J. D., & Guo, G. L. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_228 · Cited by 67
Li, Y., Talbot, C. L., & Chaurasia, B. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00407 · Cited by 69
“demonstrated that ceramides inhibit the browning of beige adipocytes cultured ex vivo, suggesting that endogenous ceramides could be autonomous regulators of adipocyte function (55).”
BackgroundZhou, W., Chen, G., Chen, D., Ye, H., & Zeng, X. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104222 · Cited by 66
Takahashi, S., Luo, Y., Ranjit, S., Xie, C., Libby, A. E., Orlicky, D. J., Dvornikov, A. S., Wang, X. X., Myakala, K., Jones, B. A., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011913 · Cited by 67
“A mass range ofm/z 50–1200 was acquired (53).”
BackgroundSelf-citationBile acids and their effects on diabetes
Rajani, C., & Jia, W. P. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0644-x · Cited by 62
Dysregulated bile acid homeostasis: unveiling its role in metabolic diseases
Wang, Y., Xu, H., Zhou, X., Chen, W., & Zhou, H. (2024) · Medical Review · doi:10.1515/mr-2024-0020 · Cited by 73
“Interestingly, some speci fi c antagonists of intestinal FXR, such as Gly-MCA [38, 147, 172] and GUDCA [132, 133, 173], have been reported as potential therapeutic agents for metabolic diseases.”
BackgroundChondronikola, M., Harris, L. L. S., & Klein, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12527 · Cited by 61
Zhong, X., Liu, Y., Gao, X., Krausz, K. W., Niu, B., Gonzalez, F. J., & Xie, C. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00921-7 · Cited by 63
“Recent evidence suggests that regulation of farnesoid X receptor (FXR) signaling has beneficial effects on obesity [5].”
BackgroundSelf-citationZhu, C., Huai, Q., Zhang, X., Dai, H., Li, X., & Wang, H. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.78525 · Cited by 68
“In intestine-specific FXR knockout mice, the expression of ceramide synthesis genes SMPD3/4, SPTLC2 and CERS4 were suppressed in the intestine, and ceramide synthesis levels were reduced, which contributed to the improvement of HFD-induced obesity, insulin resistance and hepatic steatosis [143], MYC has an important r…”
BackgroundZhang, S., Li, R. J. W., Lim, Y.-M., Batchuluun, B., Liu, H., Waise, T. M. Z., & Lam, T. K. T. (2020) · Gut · doi:10.1136/gutjnl-2020-321757 · Cited by 58
Shu, X., Li, M., Cao, Y., Li, C., Zhou, W., Ji, G., & Zhang, L. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.750826 · Cited by 66
“Studies found that the selective intestinal FXR agonist fexaramine could improve obesity-related metabolic dysfunctions, and activate G protein-coupled bile acid receptor 1/Glucagon-like peptide-1 signaling to improve insulin sensitivity and increase adipose tissue browning (Jiang et al., 2015).”
BackgroundKoopen, A., Witjes, J., Wortelboer, K., Majait, S., Prodan, A., Levin, E., Herrema, H., Winkelmeijer, M., Aalvink, S., Bergman, J. J. G. H. M., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-323297 · Cited by 56
“13 41 Thus, the diminished FXR activation may also account for more GLP-1 availability and, according to the study of Ducastel et al , more L cells’ responsiveness to butyrate/GPR43 signaling.”
Yang, Y., & Wu, C. (2022) · Food & Function · doi:10.1039/d2fo01252a · Cited by 56
Liu, Y., Zhong, X., Lin, S., Xu, H., Liang, X., Wang, Y., Xu, J., Wang, K., Guo, X., Wang, J., et al. (2022) · Microbiome · doi:10.1186/s40168-022-01430-9 · Cited by 63
Self-citationSomm, E., Henry, H., Bruce, S. J., Aeby, S., Rosikiewicz, M., Sykiotis, G. P., Asrih, M., Jornayvaz, F. R., Denechaud, P. D., Albrecht, U., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91809 · Cited by 56
“Nevertheless, further studies are warranted to elucidate whether the specific microbiota observed in Klb–/– mice can impact host energy partitioning via changes in short-chain fatty acid production (43, 44) or intestinal BA signaling (41, 45, 46).”
BackgroundBile salts in control of lipid metabolism
Schonewille, M., de Boer, J. F., & Groen, A. K. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000303 · Cited by 56
Intestinal MYC modulates obesity-related metabolic dysfunction
Luo, Y., Yang, S., Wu, X., Takahashi, S., Sun, L., Cai, J., Krausz, K. W., Guo, X., Dias, H. B., Gavrilova, O., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00421-8 · Cited by 63
Self-citationZhang, Y., Xie, Q., You, L., Cheung, P. C. K., & Zhao, Z. (2021) · eFood · doi:10.2991/efood.k.210310.001 · Cited by 58
Zhai, Y., Zhou, W., Yan, X., Qiao, Y., Guan, L., Zhang, Z., Liu, H., Jiang, J., Liu, J., & Peng, L. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154444 · Cited by 56
Research progress on the relationship between bile acid metabolism and type 2 diabetes mellitus
Hou, Y., Zhai, X., Wang, X., Wu, Y., Wang, H., Qin, Y., Han, J., & Meng, Y. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01207-6 · Cited by 64
“In these studies, BAs (CDCA [42, 43], TUDCA [31, 44, 45], HCA [46], GUDCA [47]), FXR inhibitors (HS218[48], Gly-MCA [49, 50]), FXR agonists (Fexaramine [51, 52], GW4064 [53, 54]), FXR/TGR5 agonists (INT-767 [55]), TGR5 agonists (INT-777 [52], RO5527239 [52]), and clinical drugs (Colesevelam [56],…”
BackgroundReciprocal interactions between bile acids and gut microbiota in human liver diseases
Ikegami, T., & Honda, A. (2018) · Hepatology Research · doi:10.1111/hepr.13001 · Cited by 55
Metadata
- Authors
- Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K. W., Shi, J., Brocker, C. N., Desai, D., Amin, S. G., Bisson, W. H., Liu, Y., Gavrilova, O., Patterson, A. D., & Gonzalez, F. J.
- Affiliations
- National Institutes of Health (US)
- Peking University (CN)
- Peking University People's Hospital (CN)
- Pennsylvania State University (US)
- Oregon State University (US)
- Corresponding author
- Patterson, Andrew D.
- Gonzalez, Frank J.
- ORCID
- Venue
- Nature Communications
- Published
- 2015-12-15
- Volume
- 6
- Issue
- 1
- Pages
- 10166-10166
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4682112
- OpenAlex
- W2236340720
- Cited by
- 559
- References
- 58
- Citations by year
- 2026: 33 · 2025: 55 · 2024: 54 · 2023: 49 · 2022: 56 · 2021: 78 · 2020: 61 · 2019: 52 · 2018: 39 · 2017: 49 · 2016: 32
- FWCI
- 17.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Greater South Information System
- Funders
- Pennsylvania Department of Health
- National Natural Science Foundation of China (31401011, 81200626)
- National Institutes of Health
- National Cancer Institute
- National Institute of Environmental Health Sciences (R01ES022186, ES022186)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- farnesoid X receptor, obesity, insulin resistance, hepatic steatosis, ceramide biosynthesis, high-fat diet-induced obesity, bile acid metabolism, GW4064, ileum, metabolic dysfunction
- MeSH terms
- Receptor, Farnesoid X-Activated, Adolescent, Adult, Aged, Animals, Ceramides, Cholic Acids, Fatty Liver, Female, Glycine, Humans, Ileum, Insulin Resistance, Intestinal Mucosa, Isoxazoles, Liver, Male, Middle Aged, Obesity, Receptors, Cytoplasmic and Nuclear, Mice, Young Adult, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.